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Abstract
Docking is a powerful approach to perform virtual screening on large library of compounds,
rank the conformations using a scoring function, and propose structural hypotheses of how
the ligands inhibit the target, which is invaluable in lead optimization. Using experimentally
proven active compounds, detailed docking studies were performed to determine the mech-
anism of molecular interaction and its binding mode in the active site of the modeled yeast
α-glucosidase and human intestinal maltase-glucoamylase. All active ligands were found to
have greater binding affinity with the yeast α-glucosidase as compared to that of human
homologs, intestinal, and pancreatic maltase, by an average value of ~1.3 and ~0.8 kcal/
mol, respectively. Thirty quinoline derivatives have been synthesized and evaluated against
β-glucuronidase inhibitory potential. Twenty-four analogs, which showed outstanding β-
glucuronidase activity, have IC50 values ranging between 2.11  0.05 and 46.14  0.95 μM
than standard D-saccharic acid 1,4-lactone (IC50 = 48.4  1.25 μM). Structure activity rela-
tionship and the interaction of the active compounds and enzyme active site with the help of
docking studies were established. In addition, Small series of morpholine hydrazones syn-
thesized to form morpholine hydrazones scaffold. The in vitro anti-cancer potential of all
these compounds were checked against human cancer cell lines such as HepG2 (Human
hepatocellular liver carcinoma) and MCF-7 (Human breast adenocarcinoma). Molecular
docking studies were also performed to understand the binding interaction.
Keywords: docking studies, α-glucosidase inhibitors, cedryl acetate, quinoline,
β-glucuronidase inhibitors, morpholine hydrazone
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1. Introduction
Due to the current problems and complicated challenges faced by medicinal chemists docking
is a most demanding and efficient discipline in order to rational design new therapeutic agents
for treating the human disease. Previously, the strategy for discovering new drugs consisted of
taking a lead structure and developing a chemical program for finding analog molecules
exhibiting the desired biological properties, the whole process involved several trial and error
cycles patiently developed and analyzed by medicinal chemists utilizing their experience to
ultimately select a candidate analog for further development. The entire process when looked
at today, conceptually inelegant. These days picture are quite reverse after the emergence of
computational chemistry discipline in science world. The concepts used in three-dimensional
(3D) drug design are quite simple. New molecules are conceived either on the basis of similar-
ities with known reference structures or on the basis of their complementarity with the 3D
structure of known active sites. Molecular modeling is a discipline that contributes to the
understanding of these processes in a qualitative and sometimes quantitative way [1, 2].
In this chapter we have presented a brief introduction of the available molecular docking
methods, and their development and applications in drug discovery especially for synthetic
and bio-transformed derivatives.
2. Quantum mechanical calculations and molecular docking studies of
α-glucosidase inhibitors
Inhibitors of a-glucosidase regarded as a convincing therapeutic target in the development of
drugs against diseases such as obesity, diabetes, HIV, and cancer [3, 4]. In this connection, few
synthetic a-glucosidase inhibitors (AGI’s), such as acarbose, miglitol, and voglibose are in use
since last two decades. Among the six drug classes for the management of diabetes mellitus
(DM), α-glucosidase inhibitors are one of them. These inhibitors are quite target specific as
they act in the intestine locally, in contrast to other oral anti-hyperglycemic drugs, which in
addition, alter certain biochemical processes in the human body [5]. Therefore, discovery and
development of novel α-glucosidase inhibitors are urgently needed.
2.1. Cedrol, cedryl acetate: microbial transformed metabolites
Development of novel α-glucosidase inhibitors requires screening of a large number of com-
pounds. Cedryl acetate (1) and cedrol (2) are examples of newly identified α-glucosidase
inhibitors that exhibit potent inhibitory activity. The most potent compound one was selected
for microbial transformation and the transformed products were screened for the same activity.
We successfully identified several α-glucosidase inhibitors that are more potent than acarbose
[6]. However, this was the first report describing the α-glucosidase inhibitory activity of cedrol
(2), cedryl acetate (1), [7] and some of the transformed products of cedryl acetate including 10β-
hydroxycedryl acetate (3), 2α, 10β-dihydroxycedryl acetate (4), 2α-hydroxy-10-oxocedryl
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acetate (5), 3α,10β-dihydroxycedryl acetate (6), 3α,10α-dihydroxycedryl acetate (7),
10β,14α–dihydroxy cedryl acetate (8), 3β,10β-cedr-8(15)-ene-3,10-diol (9), and 3α, 8β, 10β
-dihydroxycedrol (10) as mentioned in Figure 1. Compounds one, two, and four showed
α-glucosidase inhibitory activity whereby one was more potent than the standard inhibitor,
acarbose, against yeast α-glucosidase.
The structures have been also optimized computationally at Hartree-Fock (HF) level of theory
using valence triple-zeta plus diffuse and polarization functions (6–311++G*) basis sets for
H, C, N, and O atoms to get insight into the 3D structure of these metabolites. GAMESS
package [8] has been used for all quantum chemical calculations. Molecular docking studies
have been also performed to delineate the ligand-protein interactions at molecular level using
autodock vina programs [9]. Avogadro [10], Gabedit [11], VMD [12], and Chimera [13] have
been used for the structure building, analysis, and visualization for our calculations.
2.2. α-Glucosidase inhibitory activity
Compounds one, two, four, and six were tested for inhibition of the α-glucosidase enzyme. For
the first time, the cedrol (2) and cedryl acetate (1) demonstrated α-glucosidase inhibitory with
the latter being more potent than the former. This is possibly due to the presence of an Ac
group at C (8). Overall compounds one, two, and four showed more than or comparable
activity to the standard inhibitors (Table 1). Apparently, the polar OH group lowers the
inhibitory activity toward the enzyme, as observed in compounds four and six (inactive) in
comparison to one.
2.3. Geometry optimization
The biological activity of ligands is a function of their 3D structures. Thus, it is crucial to have
an accurate description of the ligand in 3D space. Hartree-Fock (HF) approach have been used
Figure 1. Structure of cedryl acetate and its microbial derivatives.
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to obtain the structural details of all metabolites that were probed through the geometry
optimization in the gaseous-phase with valence triple-zeta plus diffuse and polarization func-
tions (6–311++G*) basis sets. We found in all the compounds studied, the distance of the bond
between C and OH is 1.421 Å. The optimized geometry of these compounds also, showed a
short length of carbonyl groups (C=O and COC=OCH3) distance of 1.208 Å. However, the
bond order was slightly higher by a value of 0.11 in the case of C=O as expected. The carbon–
oxygen bond in C-OCOCH3 was slightly larger as compared to that in CO-COCH3 (1.402 and
1.338 Å, respectively) due to a lower bond order by a value of 0.233. The presence of acetate
group (-O-CO-CH3) in the molecule was lowered the dipole moment of the molecule as could
be seen in Table 2. These compounds with a low dipole moment seem to be most active.
However, due to limited experimental inhibitory assay data, it was difficult to make a gener-
alize conclusion.
Compound IC50* (in
mM  S.E.M)
Binding energy in
kcal/mol
(Yeast a-
glucosidase)
Binding energy in kcal/mol
(Human maltase
glucoamylase)
Binding energy in kcal/mol
(Human pancreatic
amylase; 1 U33.pdb)
C-terminal
domain
(3TOP.pdb)
N-terminal
domain
(3L4T.pdb)
1 94  15 8.4 6.9 6.5 7.9
2 130  15 7.4 6.6 6.2 7.9
4 690  16 7.9 6.3 7.1 7.6
6 Inactive 8.2 6.4 6.5 7.6
Acarbose 780  20 — — — —
Deoxynojirimycin 425.6  8.14 — — — —
Table 1. α-Glucosidase inhibitory activity of compounds 1, 2, 4 and 6 with their predicted binding energies in the active
sites of yeast and mammalian α-glucosidases.
Compound Dipole (Debye)
1 2.03
2 3.03
3 2.87
4 3.87
5 5.07
6 3.90
7 4.09
8 3.93
9 2.65
10 6.01
Table 2. Dipole moment of metabolites calculated at HF/6–311++G* level of theory and basis sets.
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2.4. Molecular docking studies
The most ideal is to obtain the orientation of ligand in 3D space into the protein binding site for
determination of ligand activity. The ligand-protein binding mode and interaction are a very
crucial to understand the catalytic activity. This modeled protein has been used as our target
protein. In Addition, to elucidate their binding activity with mammalian α-glucosidase, we
performed molecular docking studies of the human intestinal and pancreatic maltase glucoam-
ylase with the active compounds. We found no significant difference in the binding affinity of
active ligands with yeast α-glucosidase and the human pancreatic maltase glucoamylase. How-
ever, some differences in the binding energy were observed when ligands bind with the human
intestinal maltase (Table 1). The structural changes in the binding sites of these proteins are
Figure 2. (a) Homology model of the yeast α-glucosidase (yellow color) showing the ligand cluster (variable color;
licorice) into the binding site. The red color indicates the amino acid residues (labeled in white) surrounding the binding
site (b). The lower picture (c) displays the binding site cavity with the ligand cluster.
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postulated to be the cause of this less affinity of ligands toward intestinal maltase as compared to
the yeast α-glucosidase. Figure 2a shows the homology model of the yeast α-glucosidase with
the ligand cluster into the binding site. Figure 2b displays the close view of the binding site with
the best predicted orientation of ligands 1–15, obtained from the molecular docking studies,
almost overlapping with each other to form a cluster. The amino acid residues forming the
binding site cavity have been labeled in white. The cavity can be clearly visualized when the
protein is shown with the surface model as depicted in Figure 2c.
Figure 3 displays the interactions of individual metabolites one, two, four, and six with the
yeast α-glucosidase protein. Polar amino acid residues, that is, Asp349 and Arg439 have strong
H-bonding with the acetate group of the ligand. Cedryl acetate (1) exhibits the strongest
binding affinity with the protein as inferred by its lowest binding energy (8.4 kcal/mol), the
values are given in Table 1. Compound one had the lowest IC50 of 94 15 μM, which makes it
Figure 3. Ligand-protein interaction studies of compounds (a) 1, (b) 2, (c) 4, and (d) 6. The hydrogen bonds are shown as
black dotted lines. The H-bond distances in Å are given in boxes. The amino acid residues in the binding pockets are
indicated as red.
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in agreement with the enzymatic assay. The metabolite 2, showed no interaction with the
residues. The acetate group of metabolite two has been hydrolyzed to form hydroxyl group
that may play a partial role in its low activity (Figure 3b) as compared to the compound one.
Metabolites four and six are acetylated and they do form H-bonds with Asp349 and Arg439,
thereby showing a good ligand-protein binding energy, however, their activity is dramatically
lowered or diminished as compared to compound one. This attenuate activity of metabolites
four and six may be associated with their high-polarity arising from the introduction of two
hydroxyl groups into the rings, partially due to the fact that the neighboring residues around -
OH are slightly hydrophobic in nature.
3. Molecular docking studies of novel quinoline derivatives as potent
β-glucuronidase inhibitors
Glucuronidase has been used in numerous biotechnology and research applications. Glucu-
ronidase as a gene has been studied as a positive selection marker for transformed plants,
bacteria, and fungi carrying glucuronidase gene [14, 15]. It is also widely has been used for the
structural investigations of proteoglycans and for research purposes in many diagnostic
research laboratories [16].
3.1. Novel quinoline derivatives as potent β-glucuronidase inhibitors
Quinoline is an aromatic compound having an aza-heterocyclic ring. It possesses a weak
tertiary base that can undergo both nucleophilic and electrophilic substitution reactions. The
quinoline moiety is present in several pharmacologically active compounds as it does not harm
humans, when it is orally absorbed or inhaled.
Various classes of compounds that showed considerable potential as β-glucuronidase inhibitors
involved benzothiazole, bisindolylmethanes, bisindolylmethane-hydrazone, benzimidazole,
unsymmetrical heterocyclic thioureas, 2,5-disubtituted-1,3,4-oxadiazoles with benzimidazole
backbone, and benzohydrazone–oxadiazole [17]. In continuation of this work our study identi-
fied novel series of potent β-glucuronidase inhibitors of quinoline for further investigation [18].
3.2. β-Glucorinadase inhibitory activity
Thirty analogs of quinoline were synthesized, which have varied degree of β-glucorinadase
inhibition ranging in between 2.11  0.05 and 80.10  1.80 μM, when compared with the
standard inhibitor D-saccharic acid 1,4 lactone having IC50 value 48.4  1.25 μM. Out of these
thirty analogs, twenty four analogs 1–30 showed outstanding β-glucorinadase inhibitory
potential with IC50 values (Table 3) analogs 17, 20, 21, and 27–29 showed good β-glucorin-
adase inhibitory potential. The structure–activity relationship studies suggested that the β-
glucuronidase inhibitory activities of this class of compounds are mainly dependent upon the
substitutions on the phenyl ring.
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Quinoline hydrazones (1-30)
No R IC50  SEM
a [μM] No R IC50  SEM
a [μM]
1 18.40  0.45 16 16.60  0.55
2 42.25  0.80 17 78.90  1.50
3 24.20  0.40 18 44.10  0.70
4 9.20  0.30 19 19.40  0.90
5 37.01  0.70 20 68.38  1.25
6 26.30  0.50 21 49.38  0.90
7 38.50  0.80 22 9.60  0.20
8 6.70  0.25 23 8.30  0.20
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The most potent inhibition was noted in analog 13 that have hydroxy groups at 3, 4-positions
on the phenyl part. Making comparison of analog 13 having IC50 value 2.11  0.05 μM with
other dihydroxy analogs such as 12, 14, and 15 having IC50 values 3.10  0.10, 5.01  0.20, and
9 18.10  0.40 24 18.00  0.30
10 9.60  0.20 25 22.30  0.45
11 46.14  0.95 26 38.50  0.80
12 3.10  0.10 27 51.00  1.25
13 2.11  0.05 28 80.10  1.80
14 5.01  0.20 29 69.40  1.30
15 2.60  0.05 30 46.10  0.85
D-Saccharic acid 1,4-lactone 48.4  1.25
a IC50 values are expressed as mean ± standard error of mean.
Table 3. Different quinoline derivatives and their β-glucuronidase activity.
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2.60  0.05 μM, respectively, analog 13 was found to be superior than other. In analog 13 the
two hydroxy groups are present at meta-para position while in analog 12 the two hydroxy
groups are present at ortho-para positions, in analog 14 the two hydroxy groups are present at
ortho-meta positions, and in analog 15 the two hydroxy groups are present at ortho-meta
positions. The little bit difference in the activity of these analogs may be due to the difference
in position of the substituents on the phenyl part.
Similarly, effect of substituent position was also observed in other analogs such as 4, 5, and 6
having fluoro group. If we compare analog four, a ortho analog, having IC50 value 9.20 0.30 μM
with analog five, a meta analog, and six, a para analog having IC50 values 37.01  0.70 and
26.30 0.50 μM, respectively. In analog four the fluoro group is present at ortho position while in
analog five the floro group is present atmetaposition and in analog six the floro group is present at
para position. These three analogs demonstrated minute differences in their activity possibly due
to the difference in the position of the substituents of the phenyl section. Thiswas also observed in
monohydroxy analogs. From these findings, we concluded that the factors that influence the
inhibitory potentials of these analogs include the nature, position, and the number of substituents.
3.3. Docking studies
Molecular docking is a useful tool to obtain data on binding mode and to validate experimen-
tal results of active derivatives within the active site of β-D-glucuronidase. By using X-ray
crystal structure of the human β-glucuronidase enzyme at 2.6 Å resolution (PDB ID: 1BHG) [19],
it can be used to identify predict the binding modes involved in the inhibition activity.
Utilizing docking approach, we identified the stable binding mode of six most active com-
pounds (8, 12–15, and 23) that was further used in characterizing their inhibitory activity.
Compounds with the most stable binding conformation suggest to strongly alignment to the
core of β-glucuronidase. In Figure 4 shows that the quinolone moiety of these active com-
pounds are oriented toward the active pocket and share some common interaction with
catalytically important amino acids such as Glu450, Glu541, and Tyr504.
We predict that the hydrogen bonding interaction between the hydroxyl at C-4 of quinoline
moiety and Glu451 plays a vital role. According to the docking result compound 13 (Figure 5),
Figure 4. Active compounds aligned well into the binding cavity of β-glucuronidase enzyme.
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was found to be to most active compound in this series, because of the hydroxyl (OH) at C-4
involved in hydrogen bonding with Oε2 of Glu451 side chain (1.99 Å). The complex is stabi-
lized by pi-donor hydrogen bond formation between the benzene ring on quinoline moiety and
with hydroxyl (OH) of Tyr508 (3.73 Å). Two interactions were detected in hydrazone linkage
between carboxamide and the surrounding residues. The hydrazone carbonyl (C=O) oxygen
linked by a hydrogen bonding with the nitrogen on the backbone of Tyr504 (2.77 Å), another
hydrogen bond forms between the NH group and the oxygen on side chain of Asn484 with a
bond length of 3.10 Å. The two hydroxyls on the benzylidene moiety at meta positions also,
involved in hydrogen bonds with indole nitrogen at Trp528 backbone having a distance of 2.11
and 1.99 Å, respectively.
Compound 15 showed that hydroxyl (OH) at C-4 of quinoline moiety for compound formed
hydrogen bonding with Oε2 of Glu451 side chain at a longer distance (2.24 Å) as compared to
previous compound (Figure 6). In this compound the quinoline benzene rings on forms a
pi-donor hydrogen bond with hydroxyl (OH) of Tyr508 at (3.96 Å). It was also observed that
hydrazone linkage was oxygen of carbonyl (C=O) interacts with side chain of Tyr504 through a
hydrogen bond at a distance of 2.80 Å. Both form hydrogen bonds were formed between
hydroxyls at ortho and meta position on the benzylidene moiety and nitrogen of indole back-
bone of Tyr508 at a distance of 2.19 and 1.99 Å, respectively. Compound 15 was found to be a
second most active inhibitor.
In third most active compound 12 (Figure 7), it was observed that hydroxyl (OH) at Carbon no
4 exhibited hydrogen bonding with Oε2 of Glu451 side chain with a distance of 2.11 Å. On the
other hand we noted that a more stable pi-donor hydrogen bond with hydroxyl (OH) of Tyr508
at (3.77 Å) and benzene ring on quinoline moiety when compared with derivative 14. Docking
studies also showed the hydrazone linkage interaction of oxygen of carbonyl (C=O) with side
chain of Tyr504 through a hydrogen bond with length of 2.99 Å. There is also a hydrogen
Figure 5. Best binding position of compound 13 in active pocket of β-glucuronidase enzyme.
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bonding of hydroxyl at ortho position on the benzylidene with the oxygen of Asn502 (1.87 Å),
while the other another hydrogen bonding of hydroxyl at para position on the benzylidene
with the nitrogen of indole backbone of Trp528 (1.89 Å).
4. Morpholine hydrazone scaffold: synthesis, anticancer activity, and
docking studies
Cancer is a broad term to describe a disease that characterized by the uncontrolled prolifera-
tion of cells resulting from the disruption or dysfunction of regulatory signaling pathways that
Figure 7. Binding position of compound 12 in an active pocket of the β-glucuronidase enzyme.
Figure 6. Binding positions of compound 15 in an active pocket of the β-glucuronidase enzyme.
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are normally under tight control [20, 21]. In modern life, cancer is one of the big health killers.
According to the American Association for cancer research (AACR) cancer progress report
2013, it expected that 580,350 Americans would die from the various type of cancer in the same
year. Luckily, ultimate evolution has made against cancer. Approximately, from 1990 to 2012
almost 1,024,400 lives saved [22].
Currently chemotherapy is an ultimate clinic treatment to repel cancer [23]. Cisplatin drug has
been commonly used in cancer treatment for decades [24, 25]. Though, its clinical value tends
to be inadequate by the abrupt increase of drug resistance or new side effects [26]. Conse-
quently, the exploration of unusual chemotherapeutic agents has sparked the great attention of
scientists from varied disciplines.
The morpholine scaffold has been found to be an outstanding pharmacophore in medicinal
chemistry and a number of molecules having morpholine skeleton are the clinically approved
drugs [27]. N-substituted morpholines are used in the treatment of inflammatory diseases,
such as migraine and asthma [28]. Morpholines derivatives have reported to possess activity
such as platelet aggregation inhibitors, anti-eme-tics, and bronchodilators [29]. Morpholine
analogs establish a new antifungal chemical entity not allied with other presently available
medications with anti-fungal potential. The benefit in synthesizing morpholine analogs resides
in the fact that these molecules offer chlorohydrates that are water soluble for pharmacological
assays [30, 31].
Recently, we have reported synthesis, characterization, anti-cancer activity, and molecular
docking studies of morpholine derivatives [32]. A small series of morpholine hydrazones
synthesized by treating 5-morpholinothiophene-2-carbaldehyde with different aryl hydrazides
to form morpholine hydrazones scaffold (1–17) (Table 4). The in vitro anti-cancer potential of
all these compounds were checked against human cancer cell lines such as HepG2 (Human
hepatocellular liver carcinoma) and MCF-7 (Human breast adenocarcinoma). Analogs 13 had
similar substantial cytotoxic effects toward HepG2 with IC50 value 6.31  1.03 μmol/L when
compared with the standard doxorubicin (IC50 value 6.00  0.80 μmol/L); while compounds
five, eight, and nine showed potent cytotoxicity against MCF-7 with IC50 value 7.08  0.42,
1.26  0.34, and 11.22  0.22 μmol/L, respectively, when compared with the standard Tamox-
ifen (IC50 = 11.00  0.40 μmol/L). Molecular docking studies also performed to understand the
binding interaction.
4.1. In vitro anti-cancer activity
All synthesized analogs (1–17) were screened against two human cancer cell lines, human
breast carcinoma (MCF-7) and human liver carcinoma (HepG2). The potentials of these ana-
logs calculated in IC50 value shown in Table 5. Among the series 10 compounds showed
potential against HepG2 and six compounds showed potential against MCF-7.
Among them compound eight was found to be the excellent inhibitor against MCF-7 with IC50
value 1.26  0.34 μmol/L, which is more potent than the standard inhibitor Tamoxifen
(IC50 = 11.00  0.40 μmol/L). Secondly, the compound five was found to be more potent with
IC50 value 7.08  0.42 μmol/L almost two fold better than the standard. The analogs such as
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Table 4. Various analogs of morpholine.
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two, seven, nine, and 11 also showed potent inhibition for this cell line, while remaining
analogs found to be completely in active.
Compound 13 showed potent inhibition against HepG2 with IC50 value 6.31  1.03 μmol/L
when compared with the standard Doxorubicin (IC50 value 6.00  0.80 μmol/L). Compound
four and six were found second and third most active analogs among the series with IC50 value
7.94  7.94 and 12.59  1.22 μM, respectively. Other analogs such as five, seven, nine, 11, 12,
14, and 15 also showed good to moderate potential.
Molecular docking studies were performed to investigate the binding mode of the active
compounds.
4.1.1. Molecular docking analysis of morpholinothiophene hydrazone compounds
The molecular docking procedure was widely used to predict the binding interaction of the
compound in the binding pocket of the enzyme. The 3D crystal structure of the topoisomerase II
enzyme (PDB id: 4FM9)was retrieved from the protein data bank.All the ions andwatermolecules
removed and the hydrogen atoms added to the enzyme by the 3Dprotonation using theMolecular
Operating Environment (MOE) software. The target enzymes were then energy minimized by the
default parameters of the MOE for the stability and further assessment of the enzyme. The struc-
tures of the analogs of themorpholinothiophene hydrazone compounds built inMOE and energy
minimized using theMMFF94x force field and gradient 0.05. The active site pocket of the enzyme
found out by the site-finder implemented in the MOE software. The synthesized compounds
docked into the active site of the target enzyme in MOE by the default parameters, that is,
placement: Triangle matcher, Rescoring, and London dG. For each ligand, 10 conformations gen-
erated. The top-ranked conformation of each compound used for further analysis.
Molecular docking studies predicted the proper orientation of the compound five inside the
binding pocket of topoisomerase II enzyme. From the docking conformation of this active
compound, we have observed a docking score of (11.4975), which correlates well to the
biological activities (IC50 = 19.95  0.63 μmol/L in HepG2 and 7.08  0.42 μmol/L in MCF-7
S. No. HepG2 MCF-7 S. No. HepG2 MCF-7
2 — 30.0  1.00 9 40.0  0.93 11.22  0.22
4 7.94  7.94 — 11 19.95  1.31 41.67  1.62
5 19.95  0.63 7.08  0.42 12 31.0  2.26 —
6 12.59  1.22 — 13 6.31  1.03 —
7 20.0  0.32 14.13  1.42 14 56.23  0.56 —
8 — 1.26  0.34 15 15.85  0.82 —
Doxorubicin 6.00  0.80 —
Tamoxifen — 11.00  0.40
Cisplatin 12.00  0.33 15.00  0.80
Table 5. Anti-cancer activity data (IC50 values in μmol/L) of morpholine derivatives (1–17).
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cell lines). The compound was observed making two interactions with active residues of the
active site pocket of the enzyme. The oxygen atom of the morpholine moiety of the compound
formed side chain acceptor interaction with the Lys 990 residue of the binding pocket. Arg 929
was observed making the hydrogen bond with the –NH group of the hydrazine moiety of the
ligand as shown in the Figure 8. The electro-negative nature of Cl, O, and S of the substituent
moiety may increase the polarizability of the ligand by electrons withdrawing inductive effect
resulting in the enhanced potency and interactions.
5. Conclusion
The molecular docking is now fully recognized and integrated in the research process. In the
past the emergence of this new discipline had occasionally encountered some opposition here
and there. At presents, the science is mature and there are a growing number of success stories
that continuously expand the armory of drug research. Several considerations that can greatly
improve the success and enrichment of true bioactive hit compounds are commonly
overlooked at the initial stages of a molecular docking study. In this chapter, we tried to cover
several of these considerations, including few examples, of molecular docking studies of
natural and synthetic analogs of potent α-glucosidase inhibitors, β-glucuronidase inhibitors,
and cytotoxicity from our own findings. These molecular studies were performed for different
classes of bioactive compounds in order to understand the binding interaction of the active
compounds. It was concluded that the nature, position as well as the number of substituents
affects the inhibitory potential of these analogs.
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